Anavex Life Sciences Stock Just Shot Up 7% Today Here's An Important Update

2025-10-02 09:00:35

(MENAFN- AsiaNet News)

Anavex Life Sciences (AVXL) on Thursday said that its investigational drug achieved its primary endpoint in a mid-stage trial and demonstrated safety and tolerability in adults with Schizophrenia.

Shares of the company soared 7% in Thursday's pre-market session.

The company said that the safety profile of ANAVEX3-71 was consistent with previous studies in healthy volunteers, and no serious treatment-emergent adverse events were reported in the study. The company is evaluating the drug in the treatment of Schizophrenia, a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide.

Get updates to this developing story <directly on Stocktwits.

MENAFN02102025007385015968ID1110142126

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.